Ieq Capital LLC Buys 4,381 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Ieq Capital LLC significantly increased its stake in Regeneron Pharmaceuticals by 114.1%, owning 8,219 shares valued at approximately $5.2 million.
• Regeneron reported quarterly earnings of $12.89 per share, exceeding analysts' expectations of $8.43, with total revenue of $3.68 billion.
• The company announced a quarterly dividend of $0.88 per share, resulting in an annualized yield of 0.6%, with a low payout ratio of 8.87%.

Ieq Capital LLC increased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 114.1% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 8,219 shares of the biopharmaceutical company's stock after acquiring an additional 4,381 shares during the period. Ieq Capital LLC's holdings in Regeneron Pharmaceuticals were worth $5,213,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also bought and sold shares of REGN. Marietta Wealth Management LLC grew its position in shares of Regeneron Pharmaceuticals by 30.2% in the first quarter. Marietta Wealth Management LLC now owns 10,778 shares of the biopharmaceutical company's stock valued at $6,836,000 after purchasing an additional 2,501 shares during the last quarter. GAMMA Investing LLC lifted its position in shares of Regeneron Pharmaceuticals by 89,825.0% during the 1st quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock worth $517,291,000 after buying an additional 814,713 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in Regeneron Pharmaceuticals by 3.9% in the first quarter. China Universal Asset Management Co. Ltd. now owns 25,629 shares of the biopharmaceutical company's stock valued at $16,255,000 after buying an additional 955 shares in the last quarter. KBC Group NV grew its position in Regeneron Pharmaceuticals by 9.4% in the first quarter. KBC Group NV now owns 149,440 shares of the biopharmaceutical company's stock valued at $94,779,000 after acquiring an additional 12,793 shares during the last quarter. Finally, Lmcg Investments LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 231.3% in the first quarter. Lmcg Investments LLC now owns 14,481 shares of the biopharmaceutical company's stock worth $9,184,000 after acquiring an additional 10,110 shares during the last quarter. Institutional investors own 83.31% of the company's stock.

Wall Street Analysts Forecast Growth

REGN has been the subject of several research reports. Morgan Stanley reissued an "overweight" rating and issued a $761.00 price objective (up previously from $754.00) on shares of Regeneron Pharmaceuticals in a research note on Friday, August 1st. Guggenheim upped their price objective on Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the company a "buy" rating in a research note on Friday, August 1st. Canaccord Genuity Group reissued a "buy" rating and set a $850.00 target price on shares of Regeneron Pharmaceuticals in a report on Wednesday, July 23rd. Citigroup restated a "buy" rating and issued a $650.00 price target on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Finally, Rothschild & Co Redburn began coverage on shares of Regeneron Pharmaceuticals in a report on Thursday, August 14th. They set a "buy" rating and a $890.00 price target on the stock. Three investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $817.67.

Regeneron Pharmaceuticals Trading Down 2.2%

Regeneron Pharmaceuticals stock traded down $12.66 during trading hours on Wednesday, reaching $565.24. 589,904 shares of the company's stock were exchanged, compared to its average volume of 1,100,075. The firm's 50 day simple moving average is $559.74 and its 200 day simple moving average is $586.24. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $1,182.31. The company has a quick ratio of 3.72, a current ratio of 4.60 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $59.91 billion, a PE ratio of 14.25, a PEG ratio of 1.93 and a beta of 0.35.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, topping the consensus estimate of $8.43 by $4.46. The business had revenue of $3.68 billion during the quarter, compared to analysts' expectations of $3.30 billion. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The firm's revenue was up 3.6% on a year-over-year basis. During the same quarter last year, the firm posted $11.56 earnings per share. Research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th will be paid a $0.88 dividend. The ex-dividend date is Monday, August 18th. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. Regeneron Pharmaceuticals's payout ratio is currently 8.87%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.